nference, a Cambridge, Massachusetts company that builds AI infrastructure for biomedical research, announced a strategic collaboration with Novo Nordisk on November 18, 2026, to advance the study of cardiometabolic disease, including obesity, diabetes and cardiovascular disease

2

1

.

What each side brings

The companies say pooling Novo Nordisk's clinical trial data with nference's AI tools and data network will deepen understanding of cardiometabolic disease and help generate evidence for future treatments

2

1

. Researchers from both companies plan to study how well treatments work, their safety, how diseases progress and health over the long term

2

1

. The work draws on clinical studies, medical records and diagnostic data under privacy and governance safeguards

2

1

.

nference's AI platform is intended to sift that data for patterns in how diseases progress and how treatments perform in the real world, information that could shape future therapies

2

1

.

nference says it already holds long-term data partnerships with major academic medical centers, including Mayo Clinic and Duke Health

1

. Novo Nordisk, for its part, traces a century of work in metabolic medicine

1

. Venky Soundararajan, nference's founder and co-CEO, called the partnership an honor, pointing to that heritage

1

. Novo's Jacob Sten Petersen, who leads R&D external innovation, said: "We see a significant opportunity to use AI and data to deepen our understanding of cardiometabolic disease and help improve future treatments."

1

Beyond the research

The collaboration also includes a framework for exploring potential new health-focused ventures, aimed at AI-native companies working on gaps in cardiometabolic health and healthy ageing

1

. No ventures have been announced; the framework, as described, is for exploring whether any potential ones should be.

© 2026 TheOutpost.AI All rights reserved